上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
Pralatrexate (Synonyms: 普拉曲沙) 纯度: 98.30%
Pralatrexate 是一种抗叶酸剂,也是一种有效的二氢叶酸还原酶 (DHFR) 抑制剂,Ki 值为 13.4 pM。Pralatrexate 是叶酰聚谷氨酸合成酶的底物,具有改善的细胞摄取和保留能力。Pralatrexate 具有抗肿瘤活性,并可用于复发/难治性 T 细胞淋巴瘤的研究。
Pralatrexate Chemical Structure
CAS No. : 146464-95-1
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
Free Sample (0.1-0.5 mg) | Apply now | ||
10 mM * 1 mL in DMSO | ¥1261 | In-stock | |
5 mg | ¥1200 | In-stock | |
10 mg | ¥2000 | In-stock | |
50 mg | ¥6650 | In-stock | |
100 mg | ¥11500 | In-stock | |
200 mg | 询价 | ||
500 mg | 询价 |
* Please select Quantity before adding items.
Pralatrexate 相关产品
•相关化合物库:
- Covalent Screening Library Plus
- Drug Repurposing Compound Library Plus
- FDA-Approved Drug Library Plus
- FDA-Approved Drug Library Mini
- Bioactive Compound Library Plus
- Apoptosis Compound Library
- Cell Cycle/DNA Damage Compound Library
- FDA-Approved Drug Library
- Anti-Cancer Compound Library
- Peptidomimetic Library
- Anti-Aging Compound Library
- Drug Repurposing Compound Library
- Covalent Screening Library
- Anti-COVID-19 Compound Library
- FDA Approved & Pharmacopeial Drug Library
- Drug-Induced Liver Injury (DILI) Compound Library
- Anti-Blood Cancer Compound Library
- Targeted Therapy Drug Library
- Anti-Cancer Metabolism Compound Library
- Targeted Diversity Library
- Rare Diseases Drug Library
生物活性 |
Pralatrexate is an antifolate and is a potent dihydrofolate reductasean (DHFR) inhibitor with a Ki of 13.4 pM. Pralatrexate is a substrate for folylpolyglutamate synthetase with improved cellular uptake and retention. Pralatrexate has antitumor activities and has the potential for relapsed/refractory T-cell lymphoma treatment[1][2][3][4]. |
IC50 & Target |
Ki: 13.4 pM (Dihydrofolate reductasean (DHFR))[4] |
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
体外研究 (In Vitro) |
Pralatrexate (100 pM-200 µM; 48-72 hours; T-lymphoma cell lines) treatment exhibits concentration- and time-dependent cytotoxicity against a broad panel of T-lymphoma cell lines. The IC50 values at 48 and 72 hours, respectively, are as follows: H9 cells, 1.1 nM and 2.5 nM; P12 cells, 1.7 nM and 2.4 nM; CEM cells, 3.2 nM and 4.2 nM; PF-382 cells, 5.5 nM and 2.7 nM; KOPT-K1 cells, 1 nM and 1.7 nM; DND-41 cells, 97.4 nM and 1.2 nM; and HPB-ALL cells, 247.8 nM and 0.77 nM. HH cells are relatively resistant after 48 hours of exposure, with the IC50 at 72 hours being 2.8 nM[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. Cell Cytotoxicity Assay[1]
Apoptosis Analysis[1]
Western Blot Analysis[1]
|
||||||||||||||||||||||||
体内研究 (In Vivo) |
The addition of Pralatrexate (15 mg/kg; intraperitoneal injection; on days 1, 4, 8, and 11; SCID-beige mice) to Bortezomib (0.5 mg/kg) enhanced efficacy compared with either drug alone[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
|
||||||||||||||||||||||||
Clinical Trial |
|
||||||||||||||||||||||||
分子量 |
477.47 |
||||||||||||||||||||||||
Formula |
C23H23N7O5 |
||||||||||||||||||||||||
CAS 号 |
146464-95-1 |
||||||||||||||||||||||||
中文名称 |
普拉曲沙 |
||||||||||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||||||||||
储存方式 |
|
||||||||||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : ≥ 50 mg/mL (104.72 mM) * “≥” means soluble, but saturation unknown. 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||||||||||
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务